|
|
News Breaks | | | | February 21, 2013 | | 08:36 EDT |  | ACHN | Achillion equity offering reduces finance concerns, says RW Baird at RW Baird
Baird believes Achillion's secondary offering will reduce concerns surrounding its finances and remains bullish on the shares. The firm noted the company's guidance and pipeline updates and believes the shares are at an attractive entry point. Baird continues to believe Achillion will play a meaningful role in the Hep commercial landscape. Shares are Outperform rated with a $16 price target. | |
|
News For ACHN From The Last 14 Days Check below for free stories on ACHN the last two weeks. |
|
|
| May 16, 2013 | | 10:30 EDT |  | ACHN | Achillion management to meet with Maxim
 Subscribe for More Information | | | May 15, 2013 | | 06:06 EDT |  | ACHN | Achillion appoints Dr. David Apelian as Chief Medical Officer
Achillion (ACHN) appointed David Apelian, M.D., Ph.D., MBA, to the position of Executive VP and Chief Medical Officer, effective May 28. Dr. Apelian wll assume responsibility for the clinical development of Achillion's portfolio of compounds to treat HCV. In addition, Achillion also expanded its clinical operations group with the recent addition of Kevin Kucharski, formerly head of clinical operations at Pharmasset (VRUS), who will serve as Senior VP of Clinical Operations. | | | May 7, 2013 | | 06:08 EDT |  | ACHN | Achillion reports Q1 EPS (14c), consensus (15c)
Subscribe for More Information | |
|
|
|
|
|
|
